This led to the discovery of several CXCR4-targeting compounds capable of inhibiting HIV infection in CD4-positive T-lymphocytes, including the cyclams, polyphemusin II and analogs derived thereof. This evidence concerns the gene CXCR4 and HIV infectious disease.